Amylyx Pharmaceuticals Inc (AMLX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Joshua B. Cohen
Employees:
200
43 THORNDIKE STREET, CAMBRIDGE, MA 02141
617-683-0917

Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.

Data derived from most recent annual or quarterly report
Market Cap 1.003 Billion Shares Outstanding67.378 Million Avg 30-day Volume 1.95 Million
P/E Ratio695.586 Dividend Yield0.0 EPS-0.92
Price to Revenue4.3406 Debt to Equity0.0 EBITDA-17.504 Million
Price to Book Value3.0523 Operating Margin-2.6256000000000004 Enterprise Value922.051 Million
Current Ratio9.516 EPS Growth1.003 Quick Ratio8.427
1 Yr BETA 1.2426 52-week High/Low 41.93 / 11.82 Profit Margin0.624
Operating Cash Flow Growth67.599 Free Cash Flow to Firm (FCFF) TTM -84.41 Million Free Cash Flow to Equity (FCFE) TTM-3.995 Million
Altman Z-Score16.5379

Are you looking for this stock instead?

View SEC Filings from AMLX instead.

View recent insider trading info

Funds Holding AMLX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AMLX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-13:
    Item 8.01: Other Events
  • 8-K: filed on 2023-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-26:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-09:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-14:
    Item 7.01: Regulation FD Disclosure
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    63.7 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BEDROSIAN CAMILLE L CHIEF MEDICAL OFFICER

    • Officer
    0 2023-11-27 2

    COHEN JOSHUA B CO-CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    2,906,311 2023-11-16 3

    FRATES JAMES M CHIEF FINANCIAL OFFICER

    • Officer
    125,823 2023-10-31 7

    MORNINGSIDE VENTURE INVESTMENTS LTD

    • 10% Owner
    4,997,302 2023-08-15 10

    MAZZARIELLO GINA CHIEF LEGAL OFFICER

    • Officer
    49,083 2023-08-15 4

    OLINGER MARGARET CHIEF COMMERCIAL OFFICER

    • Officer
    251,108 2023-07-12 4

    MILNE GEORGE M JR

    • Director
    0 2023-06-08 3

    QUIMI DAPHNE

    • Director
    0 2023-06-08 1

    FONTEYNE PAUL R.

    • Director
    0 2023-06-08 1

    FIRESTONE KAREN

    • Director
    0 2023-06-08 3

    YERAMIAN PATRICK D CHIEF MEDICAL OFFICER

    • Officer
    208,417 2023-05-15 5

    KLEE JUSTIN B. CO-CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    2,842,617 2023-03-16 2

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    VIKING GLOBAL OPPORTUNITIES PARENT GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    DRAGSA 96 LLC

    • 10% Owner
    5,770,536 2022-09-08 0

    ALS INVEST 1 B.V.

    • 10% Owner
    5,895,280 2022-07-06 0

    CHENG ISAAC

    • Director
    19,000 2022-06-09 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    VIKING GLOBAL OPPORTUNITIES PARENT GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    7,170,536 2022-01-11 0

    DRAGSA 96 LLC

    • 10% Owner
    2,300,000 2022-01-11 0

    MORNINGSIDE VENTURE INVESTMENTS LTD

    MVIL, LLC

    • 10% Owner
    10,678,808 2022-01-06 10

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BEDROSIAN CAMILLE L - Officer CHIEF MEDICAL OFFICER

    2023-11-29 16:49:00 -0500 2023-11-27 A 58,333 a 58,333 direct 0.4237 0.4237 2 0.0 1

    BEDROSIAN CAMILLE L - Officer CHIEF MEDICAL OFFICER

    2023-11-29 16:49:00 -0500 2023-11-27 A 162,500 a 162,500 direct

    COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER

    2023-11-20 20:20:39 -0500 2023-11-16 M 63,694 $1.57 a 2,906,311 direct 0.5538 7.4367 7.4367 6 0.0 1

    COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER

    2023-11-20 20:20:39 -0500 2023-11-16 M 63,694 d 36,306 direct

    FRATES JAMES M - Officer CHIEF FINANCIAL OFFICER by trust

    2023-11-02 15:33:04 -0400 2023-10-31 G 11,072 a 11,072 indirect -2.6044 -32.2843 0.0 1 -33.478 5

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 20:15:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 19:45:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 19:15:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 18:45:03 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 18:15:03 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 17:45:03 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 17:15:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 16:45:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 16:15:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 15:45:03 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 15:15:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 14:45:04 UTC 4.3784 0.9416 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 14:15:04 UTC 4.3784 0.9416 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 13:45:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-06 13:15:04 UTC 4.4301 0.8899 1900000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-05 22:15:04 UTC 4.4301 0.8899 1800000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-05 21:45:04 UTC 4.4301 0.8899 1800000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-05 21:15:04 UTC 4.4301 0.8899 1800000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-05 20:45:04 UTC 4.4301 0.8899 1800000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-12-05 20:15:04 UTC 4.4301 0.8899 1800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund AMLX -1086.0 shares, $-25466.7 2023-07-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AMLX -10500.0 shares, $-192255.0 2023-09-30 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund AMLX -267.0 shares, $-4888.77 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments